CRMD vs KALV โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
KALV Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to KalVista Pharmaceuticals, Inc. Common Stock (KALV) driven by superior Momentum & Technical, Options & Structure while CRMD counters with relative strength in Valuation, Growth & Margin. Fundamentally, CRMD trades at 49.0x Forward P/E with 41.0% operating margin (-47.7% YoY revenue) versus KALV at 25.4x Forward P/E and -57.4% operating margin (+30.7% YoY). In options structure, CRMD sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro) against KALV sits in UNCLASSIFIED (31st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRMD | KALV | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $384.7M | $1.4B | Larger Scale | KALV |
| Trailing P/E Ratio Valuation | 2.4x | 25.4x | Lower Multiple | CRMD |
| Forward P/E Ratio Valuation | 49.0x | 25.4x | Lower Multiple | KALV |
| Revenue Growth (YoY) Growth | -47.7% | +30.7% | Higher Growth | KALV |
| Operating Margin (TTM) Profitability | 41.0% | -57.4% | Higher Margin | CRMD |
| Net Profit Margin Profitability | 15.5% | -118.7% | Higher Margin | CRMD |
| Return on Equity (ROE) Capital Efficiency | 15.3% | -190.2% | Higher ROE | CRMD |
| 52-Week Range Position Momentum | 3% ($5โ$13) | 100% ($10โ$27) | Stronger Trend | KALV |
| Beta / 30D Volatility Risk Regime | 1.20ฮฒ ยท 107% Vol | 0.85ฮฒ ยท 2% Vol | Lower Realized Risk | KALV |
| Unified Institutional Score Composite Signal | 53.2 / 100 (HOLD) | 55.1 / 100 (HOLD) | Higher Composite | KALV |